---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-011986"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T15:16:27.605992+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Windtree Therapeutics FY2024 net loss $1.8M; cash $1.8M; pivots to revenue-generating acquisitions

## Summary
- Net loss $1.8M vs $20.3M in 2023; loss per basic share $104.35 on $5.5M net loss attributable to common.
- Cash and equivalents $1.8M at Dec 31, 2024; raised ~$2.3M post-period, funding operations only through April 2025.
- New corporate strategy: use equity to acquire small biotech firms with FDA-approved products; signed Evofem deal for PHEXXI distribution.
- Positive Phase 2 SEISMiC Extension for istaroxime in early cardiogenic shock; SEISMiC C trial enrolling, interim data in Q3 2025.
- R&D spend rose to $16.3M from $8.3M, driven by $7.5M Varian IPR&D charge and increased istaroxime development costs.

## SEC filing metadata
- accession: 0001437749-25-011986
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774925011986/0001437749-25-011986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774925011986/wint20241218_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-011986
- JSON: https://secwatch.observer/filing/0001437749-25-011986.json
- Plain text: https://secwatch.observer/filing/0001437749-25-011986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.